價格 | ¥427 | ¥616 | ¥987 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-09-23 |
中文名稱:化合物 LY2811376 | 英文名稱:LY2811376 |
CAS:1194044-20-6 | 品牌: TargetMol |
產地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.01% | 產品類別: 抑制劑 |
貨號: T2639 |
名稱 | LY2811376 |
描述 | LY2811376, an orally available non-peptidic β-secretase(BACE1) inhibitor (IC50: 239-249 nM), can decrease Aβ secretion (EC50: 300 nM). It has 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including pepsin, cathepsin D, or renin. |
細胞實驗 | The cytotoxicity in the HEK293Swe cell model is assessed using a CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay. (Only for Reference) |
激酶實驗 | Determination of enzymatic ef?ciency: The stock solution for each FRET peptide substrate is prepared at 30 mM in dimethylsulfoxide (DMSO). The huBACE1:Fc muBACE1:Fc preparation is concentrated through YM10 Centricon. to a ?nal concentration of at least 7 mg/mL. The optimal enzyme concentration for each FRET peptide substrate is determined individually at 30 μM FRET peptide substrate in 50 mM ammonium acetate, pH 4.6, 1 mg/mL BSA and 1 mM Triton X-100. The enzymatic ef?ciency (kcat /Km) of either of the BACE1 orthologs toward individual FRET peptide substrates at 15, 30 and 100 μM is determined under the optimal conditions for each substrate. The progress of the reaction is monitored by measuring an increase of the emission signal at 420 nm with excitation wavelength set at 320 nm, using a GEMINI ?uorescence plate reader. Amino acid conjugated aminobenzoate is used to convert the emission signal in the relative ?uorescence units into the molar concentration of product generated in the reaction mixture. The initial phase of the timedependence curve is ?tted with a linear function whose slope is used to calculate the initial rate for huBACE1:Fc toward each peptide substrate. The kcat /Km values are calculated from the linear dependence of the initial rate on the concentration of each peptide. |
體外活性 | 在APPV717F小鼠Aβ病理模型中,LY2811376(10/30/100 mg/kg)使Aβ、sAPPβ和C99出現(xiàn)劑量依賴性的顯著減少,這些是APP被BACE1蛋白水解后最接近的分解產物.在比格犬體內,LY2811376(5 mg/kg)使血漿中的Aβ1-x減少,給藥4-12 h后最大下降85%. |
體內活性 | LY2811376濃度依賴性降低APP過表達HEK293細胞中Aβ的分泌。LY2811376濃度依賴性抑制hBACE1,包括小分子合成肽(IC50:239 nM)和較大的嵌合蛋白底物(IC50:249 nM)。在PDAPP轉基因小鼠的神經元原代培養(yǎng)物中,LY2811376抑制Aβ分泌(EC50:100 nM)。 |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 13 mg/mL (40.6 mM) Ethanol : 60 mg/mL (187.3 mM) |
關鍵字 | Inhibitor | LY 2811376 | LY-2811376 | LY2811376 | BACE | β-Secretase | inhibit | Beta-secretase |
相關產品 | Rutin | Methyl tridecanoate | Phytic acid potassium | Ginsenoside Rg2 | Notoginsenoside R1 | Tramiprosate | Deferoxamine Mesylate | Anle138b | Auraptene | Geniposide | Dihydroergocristine mesylate | Ginsenoside Re |
相關庫 | 抑制劑庫 | 經典已知活性庫 | 已知活性化合物庫 | ReFRAME 相關化合物庫 | 抗阿爾茨海默癥化合物庫 | 神經信號分子庫 | 抗心血管疾病化合物庫 | 臨床期小分子藥物庫 | 神經退行性疾病化合物庫 | 藥物功能重定位化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.2651萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 化學試劑,生物活性小分子 | 經營模式 | 貿易,試劑,定制,服務 |
產品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP3年
|
上海嘉定區(qū)澄瀏公路52號
|
2024-11-12 | |
¥699.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2024-10-31 | |
詢價 |
VIP1年
|
陜西西化化學工業(yè)有限公司
|
2024-10-15 | |
詢價 |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
詢價 |
成都伍源生物工程有限公司
|
2024-09-24 | ||
¥1131.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-08-16 | |
詢價 |
Shanghai Yusheng Medchem Co., Ltd
|
2022-05-08 |